[
  {
    "inputSequence": {
      "header": "unk",
      "SHA512": "be094e57b841b76d12f153919d865a83dd2875744824fdecba26291a846599900644c1f5ff66f780d74d36a213eeae1847b2c9148c3cdbc7694fd61dd26f508f"
    },
    "subtypeText": "B (2.80%)",
    "validationResults": [],
    "alignedGeneSequences": [
      {
        "firstAA": 1,
        "lastAA": 250,
        "gene": {
          "name": "RT",
          "length": 560
        },
        "mutations": [
          {
            "consensus": "E",
            "position": 28,
            "AAs": "K",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "K",
            "position": 32,
            "AAs": "E",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "M",
            "position": 41,
            "AAs": "L",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "L",
            "position": 74,
            "AAs": "V",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "K",
            "position": 101,
            "AAs": "EK",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "D",
            "position": 123,
            "AAs": "E",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "I",
            "position": 135,
            "AAs": "V",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "S",
            "position": 162,
            "AAs": "C",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "D",
            "position": 177,
            "AAs": "E",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "I",
            "position": 178,
            "AAs": "M",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "V",
            "position": 179,
            "AAs": "I",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "Y",
            "position": 181,
            "AAs": "C",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "M",
            "position": 184,
            "AAs": "V",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "Q",
            "position": 207,
            "AAs": "E",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "R",
            "position": 211,
            "AAs": "K",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "T",
            "position": 215,
            "AAs": "Y",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "P",
            "position": 225,
            "AAs": "H",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "V",
            "position": 245,
            "AAs": "T",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          }
        ],
        "SDRMs": [
          {
            "text": "M41L"
          },
          {
            "text": "L74V"
          },
          {
            "text": "K101E"
          },
          {
            "text": "Y181C"
          },
          {
            "text": "M184V"
          },
          {
            "text": "T215Y"
          },
          {
            "text": "P225H"
          }
        ],
        "alignedNAs": "CCCATTAGTCCTATTGAAACTGTACCAGTAAAATTAAAGCCAGGAATGGATGGTCCAAAAGTTAAACAATGGCCATTGACAAAAGAAAAAATAGAAGCATTGGTAGAAATTTGTACAGAATTGGAAAAGGAAGGAAAGATTTCAAAAATTGGGCCTGAAAATCCATACAATACTCCAGTATTTGCCATAAAGAAAAAAGACAGTACTAAATGGAGAAAAGTAGTAGATTTCAGAGAACTTAATAAGAGAACTCAAGACTTCTGGGAAGTCCAATTAGGAATACCACATCCTGCAGGGTTARAAAAGAAAAAATCAGTAACAGTACTGGATGTGGGTGATGCATATTTTTCAGTWCCCTTAGATAAAGAATTCAGGAAGTATACTGCATTTACCATACCTAGTGTAAACAATGAGACACCAGGAATTAGATATCAGTACAATGTGCTTCCACAGGGATGGAAAGGATCGCCAGCAATATTCCAATGTAGCATGACAAAAATCTTAGAGCCTTTTAGAAAACAGAATCCAGAAATGATTATCTGTCAATACGTGGATGATTTGTATGTAGGATCTGACTTAGAAATAGGGCAGCATAGAACAAAAATAGAGGAACTGAGAGAGCATTTGTTAAAGTGGGGATTTTACACACCAGACAAAAAACATCAGAAAGAACATCCATTTCTTTGGATGGGTTATGAACTCCATCCGGATAAATGGACAGTACAGCCTATAACATTGCCAGAAAAAGAC",
        "alignedAAs": "PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALVEICTELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEMIICQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFYTPDKKHQKEHPFLWMGYELHPDKWTVQPITLPEKD",
        "prettyPairwise": {
          "positionLine": [
            " 1 ",
            " 2 ",
            " 3 ",
            " 4 ",
            " 5 ",
            " 6 ",
            " 7 ",
            " 8 ",
            " 9 ",
            "10 ",
            "11 ",
            "12 ",
            "13 ",
            "14 ",
            "15 ",
            "16 ",
            "17 ",
            "18 ",
            "19 ",
            "20 ",
            "21 ",
            "22 ",
            "23 ",
            "24 ",
            "25 ",
            "26 ",
            "27 ",
            "28 ",
            "29 ",
            "30 ",
            "31 ",
            "32 ",
            "33 ",
            "34 ",
            "35 ",
            "36 ",
            "37 ",
            "38 ",
            "39 ",
            "40 ",
            "41 ",
            "42 ",
            "43 ",
            "44 ",
            "45 ",
            "46 ",
            "47 ",
            "48 ",
            "49 ",
            "50 ",
            "51 ",
            "52 ",
            "53 ",
            "54 ",
            "55 ",
            "56 ",
            "57 ",
            "58 ",
            "59 ",
            "60 ",
            "61 ",
            "62 ",
            "63 ",
            "64 ",
            "65 ",
            "66 ",
            "67 ",
            "68 ",
            "69 ",
            "70 ",
            "71 ",
            "72 ",
            "73 ",
            "74 ",
            "75 ",
            "76 ",
            "77 ",
            "78 ",
            "79 ",
            "80 ",
            "81 ",
            "82 ",
            "83 ",
            "84 ",
            "85 ",
            "86 ",
            "87 ",
            "88 ",
            "89 ",
            "90 ",
            "91 ",
            "92 ",
            "93 ",
            "94 ",
            "95 ",
            "96 ",
            "97 ",
            "98 ",
            "99 ",
            "100",
            "101",
            "102",
            "103",
            "104",
            "105",
            "106",
            "107",
            "108",
            "109",
            "110",
            "111",
            "112",
            "113",
            "114",
            "115",
            "116",
            "117",
            "118",
            "119",
            "120",
            "121",
            "122",
            "123",
            "124",
            "125",
            "126",
            "127",
            "128",
            "129",
            "130",
            "131",
            "132",
            "133",
            "134",
            "135",
            "136",
            "137",
            "138",
            "139",
            "140",
            "141",
            "142",
            "143",
            "144",
            "145",
            "146",
            "147",
            "148",
            "149",
            "150",
            "151",
            "152",
            "153",
            "154",
            "155",
            "156",
            "157",
            "158",
            "159",
            "160",
            "161",
            "162",
            "163",
            "164",
            "165",
            "166",
            "167",
            "168",
            "169",
            "170",
            "171",
            "172",
            "173",
            "174",
            "175",
            "176",
            "177",
            "178",
            "179",
            "180",
            "181",
            "182",
            "183",
            "184",
            "185",
            "186",
            "187",
            "188",
            "189",
            "190",
            "191",
            "192",
            "193",
            "194",
            "195",
            "196",
            "197",
            "198",
            "199",
            "200",
            "201",
            "202",
            "203",
            "204",
            "205",
            "206",
            "207",
            "208",
            "209",
            "210",
            "211",
            "212",
            "213",
            "214",
            "215",
            "216",
            "217",
            "218",
            "219",
            "220",
            "221",
            "222",
            "223",
            "224",
            "225",
            "226",
            "227",
            "228",
            "229",
            "230",
            "231",
            "232",
            "233",
            "234",
            "235",
            "236",
            "237",
            "238",
            "239",
            "240",
            "241",
            "242",
            "243",
            "244",
            "245",
            "246",
            "247",
            "248",
            "249",
            "250"
          ],
          "refAALine": [
            " P ",
            " I ",
            " S ",
            " P ",
            " I ",
            " E ",
            " T ",
            " V ",
            " P ",
            " V ",
            " K ",
            " L ",
            " K ",
            " P ",
            " G ",
            " M ",
            " D ",
            " G ",
            " P ",
            " K ",
            " V ",
            " K ",
            " Q ",
            " W ",
            " P ",
            " L ",
            " T ",
            " E ",
            " E ",
            " K ",
            " I ",
            " K ",
            " A ",
            " L ",
            " V ",
            " E ",
            " I ",
            " C ",
            " T ",
            " E ",
            " M ",
            " E ",
            " K ",
            " E ",
            " G ",
            " K ",
            " I ",
            " S ",
            " K ",
            " I ",
            " G ",
            " P ",
            " E ",
            " N ",
            " P ",
            " Y ",
            " N ",
            " T ",
            " P ",
            " V ",
            " F ",
            " A ",
            " I ",
            " K ",
            " K ",
            " K ",
            " D ",
            " S ",
            " T ",
            " K ",
            " W ",
            " R ",
            " K ",
            " L ",
            " V ",
            " D ",
            " F ",
            " R ",
            " E ",
            " L ",
            " N ",
            " K ",
            " R ",
            " T ",
            " Q ",
            " D ",
            " F ",
            " W ",
            " E ",
            " V ",
            " Q ",
            " L ",
            " G ",
            " I ",
            " P ",
            " H ",
            " P ",
            " A ",
            " G ",
            " L ",
            " K ",
            " K ",
            " K ",
            " K ",
            " S ",
            " V ",
            " T ",
            " V ",
            " L ",
            " D ",
            " V ",
            " G ",
            " D ",
            " A ",
            " Y ",
            " F ",
            " S ",
            " V ",
            " P ",
            " L ",
            " D ",
            " K ",
            " D ",
            " F ",
            " R ",
            " K ",
            " Y ",
            " T ",
            " A ",
            " F ",
            " T ",
            " I ",
            " P ",
            " S ",
            " I ",
            " N ",
            " N ",
            " E ",
            " T ",
            " P ",
            " G ",
            " I ",
            " R ",
            " Y ",
            " Q ",
            " Y ",
            " N ",
            " V ",
            " L ",
            " P ",
            " Q ",
            " G ",
            " W ",
            " K ",
            " G ",
            " S ",
            " P ",
            " A ",
            " I ",
            " F ",
            " Q ",
            " S ",
            " S ",
            " M ",
            " T ",
            " K ",
            " I ",
            " L ",
            " E ",
            " P ",
            " F ",
            " R ",
            " K ",
            " Q ",
            " N ",
            " P ",
            " D ",
            " I ",
            " V ",
            " I ",
            " Y ",
            " Q ",
            " Y ",
            " M ",
            " D ",
            " D ",
            " L ",
            " Y ",
            " V ",
            " G ",
            " S ",
            " D ",
            " L ",
            " E ",
            " I ",
            " G ",
            " Q ",
            " H ",
            " R ",
            " T ",
            " K ",
            " I ",
            " E ",
            " E ",
            " L ",
            " R ",
            " Q ",
            " H ",
            " L ",
            " L ",
            " R ",
            " W ",
            " G ",
            " F ",
            " T ",
            " T ",
            " P ",
            " D ",
            " K ",
            " K ",
            " H ",
            " Q ",
            " K ",
            " E ",
            " P ",
            " P ",
            " F ",
            " L ",
            " W ",
            " M ",
            " G ",
            " Y ",
            " E ",
            " L ",
            " H ",
            " P ",
            " D ",
            " K ",
            " W ",
            " T ",
            " V ",
            " Q ",
            " P ",
            " I ",
            " V ",
            " L ",
            " P ",
            " E ",
            " K ",
            " D "
          ],
          "alignedNAsLine": [
            "CCC",
            "ATT",
            "AGT",
            "CCT",
            "ATT",
            "GAA",
            "ACT",
            "GTA",
            "CCA",
            "GTA",
            "AAA",
            "TTA",
            "AAG",
            "CCA",
            "GGA",
            "ATG",
            "GAT",
            "GGT",
            "CCA",
            "AAA",
            "GTT",
            "AAA",
            "CAA",
            "TGG",
            "CCA",
            "TTG",
            "ACA",
            "AAA",
            "GAA",
            "AAA",
            "ATA",
            "GAA",
            "GCA",
            "TTG",
            "GTA",
            "GAA",
            "ATT",
            "TGT",
            "ACA",
            "GAA",
            "TTG",
            "GAA",
            "AAG",
            "GAA",
            "GGA",
            "AAG",
            "ATT",
            "TCA",
            "AAA",
            "ATT",
            "GGG",
            "CCT",
            "GAA",
            "AAT",
            "CCA",
            "TAC",
            "AAT",
            "ACT",
            "CCA",
            "GTA",
            "TTT",
            "GCC",
            "ATA",
            "AAG",
            "AAA",
            "AAA",
            "GAC",
            "AGT",
            "ACT",
            "AAA",
            "TGG",
            "AGA",
            "AAA",
            "GTA",
            "GTA",
            "GAT",
            "TTC",
            "AGA",
            "GAA",
            "CTT",
            "AAT",
            "AAG",
            "AGA",
            "ACT",
            "CAA",
            "GAC",
            "TTC",
            "TGG",
            "GAA",
            "GTC",
            "CAA",
            "TTA",
            "GGA",
            "ATA",
            "CCA",
            "CAT",
            "CCT",
            "GCA",
            "GGG",
            "TTA",
            "RAA",
            "AAG",
            "AAA",
            "AAA",
            "TCA",
            "GTA",
            "ACA",
            "GTA",
            "CTG",
            "GAT",
            "GTG",
            "GGT",
            "GAT",
            "GCA",
            "TAT",
            "TTT",
            "TCA",
            "GTW",
            "CCC",
            "TTA",
            "GAT",
            "AAA",
            "GAA",
            "TTC",
            "AGG",
            "AAG",
            "TAT",
            "ACT",
            "GCA",
            "TTT",
            "ACC",
            "ATA",
            "CCT",
            "AGT",
            "GTA",
            "AAC",
            "AAT",
            "GAG",
            "ACA",
            "CCA",
            "GGA",
            "ATT",
            "AGA",
            "TAT",
            "CAG",
            "TAC",
            "AAT",
            "GTG",
            "CTT",
            "CCA",
            "CAG",
            "GGA",
            "TGG",
            "AAA",
            "GGA",
            "TCG",
            "CCA",
            "GCA",
            "ATA",
            "TTC",
            "CAA",
            "TGT",
            "AGC",
            "ATG",
            "ACA",
            "AAA",
            "ATC",
            "TTA",
            "GAG",
            "CCT",
            "TTT",
            "AGA",
            "AAA",
            "CAG",
            "AAT",
            "CCA",
            "GAA",
            "ATG",
            "ATT",
            "ATC",
            "TGT",
            "CAA",
            "TAC",
            "GTG",
            "GAT",
            "GAT",
            "TTG",
            "TAT",
            "GTA",
            "GGA",
            "TCT",
            "GAC",
            "TTA",
            "GAA",
            "ATA",
            "GGG",
            "CAG",
            "CAT",
            "AGA",
            "ACA",
            "AAA",
            "ATA",
            "GAG",
            "GAA",
            "CTG",
            "AGA",
            "GAG",
            "CAT",
            "TTG",
            "TTA",
            "AAG",
            "TGG",
            "GGA",
            "TTT",
            "TAC",
            "ACA",
            "CCA",
            "GAC",
            "AAA",
            "AAA",
            "CAT",
            "CAG",
            "AAA",
            "GAA",
            "CAT",
            "CCA",
            "TTT",
            "CTT",
            "TGG",
            "ATG",
            "GGT",
            "TAT",
            "GAA",
            "CTC",
            "CAT",
            "CCG",
            "GAT",
            "AAA",
            "TGG",
            "ACA",
            "GTA",
            "CAG",
            "CCT",
            "ATA",
            "ACA",
            "TTG",
            "CCA",
            "GAA",
            "AAA",
            "GAC"
          ],
          "mutationLine": [
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " K ",
            " - ",
            " - ",
            " - ",
            " E ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " L ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " V ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            "KE ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " E ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " V ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " C ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " E ",
            " M ",
            " I ",
            " - ",
            " C ",
            " - ",
            " - ",
            " V ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " E ",
            " - ",
            " - ",
            " - ",
            " K ",
            " - ",
            " - ",
            " - ",
            " Y ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " H ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " T ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - "
          ]
        }
      }
    ],
    "drugResistance": [
      {
        "version": {
          "text": "8.8",
          "publishDate": "2019-02-13"
        },
        "gene": {
          "name": "RT"
        },
        "drugScores": [
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "ABC",
              "displayAbbr": "ABC"
            },
            "score": 90.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M41L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "L74V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
                      }
                    ]
                  }
                ],
                "score": 30.0
              },
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "T215Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "M41L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "T215Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "L74V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
                      }
                    ]
                  },
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 15.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "AZT",
              "displayAbbr": "AZT"
            },
            "score": 55.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M41L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": -10.0
              },
              {
                "mutations": [
                  {
                    "text": "T215Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
                      }
                    ]
                  }
                ],
                "score": 40.0
              },
              {
                "mutations": [
                  {
                    "text": "M41L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "T215Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "Intermediate Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "D4T",
              "displayAbbr": "D4T"
            },
            "score": 55.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M41L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": -10.0
              },
              {
                "mutations": [
                  {
                    "text": "T215Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
                      }
                    ]
                  }
                ],
                "score": 40.0
              },
              {
                "mutations": [
                  {
                    "text": "M41L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "T215Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "Intermediate Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "DDI",
              "displayAbbr": "DDI"
            },
            "score": 105.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M41L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "L74V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "T215Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "M41L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "T215Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "FTC",
              "displayAbbr": "FTC"
            },
            "score": 65.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "M41L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "T215Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
                      }
                    ]
                  }
                ],
                "score": 5.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "LMV",
              "displayAbbr": "3TC"
            },
            "score": 65.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "M41L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "T215Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
                      }
                    ]
                  }
                ],
                "score": 5.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "TDF",
              "displayAbbr": "TDF"
            },
            "score": 15.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M41L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": -10.0
              },
              {
                "mutations": [
                  {
                    "text": "T215Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "M41L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "T215Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "Low-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "DOR",
              "displayAbbr": "DOR"
            },
            "score": 55.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "P225H",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 30.0
              }
            ],
            "text": "Intermediate Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "EFV",
              "displayAbbr": "EFV"
            },
            "score": 95.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 30.0
              },
              {
                "mutations": [
                  {
                    "text": "P225H",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 45.0
              },
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 5.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "ETR",
              "displayAbbr": "ETR"
            },
            "score": 50.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 30.0
              },
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 5.0
              }
            ],
            "text": "Intermediate Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "NVP",
              "displayAbbr": "NVP"
            },
            "score": 140.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 30.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "P225H",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 45.0
              },
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 5.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "RPV",
              "displayAbbr": "RPV"
            },
            "score": 90.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 45.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 45.0
              }
            ],
            "text": "High-Level Resistance"
          }
        ]
      }
    ]
  }
]